Perrigo Company plc Increase (Decrease) in Prepaid Expense and Other Assets
Perrigo Company plc (PRGO) reported Increase (Decrease) in Prepaid Expense and Other Assets of $54.60 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- Perrigo Company plc increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-27 was $8.70M.
- Perrigo Company plc increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-28 was $45.90M.
- Perrigo Company plc increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $5.20M.
- Perrigo Company plc increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-27 was $3.00M, a 74.36% decline year-over-year.
- Perrigo Company plc increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$8.40M.
- Perrigo Company plc increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$20.10M.
- Perrigo Company plc increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$47.50M.
- Perrigo Company plc increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$25.90M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-27 | $8.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $54.60M 10-Q · filed 2026-08-05 | $59.80M derived: sum of 3 quarters · filed 2026-08-05 | $62.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $45.90M 10-Q · filed 2026-05-06 | $51.10M derived: sum of 2 quarters · filed 2026-05-06 | $54.10M derived: sum of 3 quarters · filed 2026-05-06 | $43.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.20M derived: sum of 2 quarters · filed 2026-02-26 | -$2.30M derived: sum of 3 quarters · filed 2026-08-05 | -$8.40M 10-K · filed 2026-02-26 |
| 2025-09-27 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$7.50M derived: sum of 2 quarters · filed 2026-08-05 | -$13.60M 10-Q · filed 2025-11-05 | -$33.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | -$10.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$16.60M 10-Q · filed 2026-08-05 | -$36.20M derived: sum of 3 quarters · filed 2026-08-05 | -$24.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | -$6.10M 10-Q · filed 2026-05-06 | -$25.70M derived: sum of 2 quarters · filed 2026-05-06 | -$14.00M derived: sum of 3 quarters · filed 2026-05-06 | -$27.90M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$19.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$7.90M derived: sum of 2 quarters · filed 2026-02-26 | -$21.80M derived: sum of 3 quarters · filed 2026-02-26 | -$20.10M 10-K · filed 2026-02-26 |
| 2024-09-28 | $11.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$2.20M derived: sum of 2 quarters · filed 2025-11-05 | -$500.00K 10-Q · filed 2025-11-05 | -$12.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-29 | -$13.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$12.20M 10-Q · filed 2025-08-06 | -$23.80M derived: sum of 3 quarters · filed 2026-02-26 | -$48.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-30 | $1.70M 10-Q · filed 2025-05-07 | -$9.90M derived: sum of 2 quarters · filed 2026-02-26 | -$34.90M derived: sum of 3 quarters · filed 2026-02-26 | -$28.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$36.60M derived: sum of 2 quarters · filed 2026-02-26 | -$30.40M derived: sum of 3 quarters · filed 2026-02-26 | -$47.50M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$18.80M derived: sum of 2 quarters · filed 2024-11-06 | -$35.90M 10-Q · filed 2024-11-06 | -$55.10M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-07-01 | $6.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$10.90M 10-Q · filed 2024-08-02 | -$30.10M derived: sum of 3 quarters · filed 2025-02-28 | -$7.30M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-04-01 | -$17.10M 10-Q · filed 2024-05-07 | -$36.30M derived: sum of 2 quarters · filed 2025-02-28 | -$13.50M derived: sum of 3 quarters · filed 2025-02-28 | -$34.90M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$19.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $3.60M derived: sum of 2 quarters · filed 2025-02-28 | -$17.80M derived: sum of 3 quarters · filed 2025-02-28 | -$25.90M 10-K · filed 2025-02-28 |
| 2022-10-01 | $22.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.40M derived: sum of 2 quarters · filed 2023-11-07 | -$6.70M 10-Q · filed 2023-11-07 | |
| 2022-07-02 | -$21.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$29.50M 10-Q · filed 2023-08-08 | ||
| 2022-04-02 | -$8.10M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2013-09-28 | $20.04K 10-Q · filed 2013-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |